Syros Pharmaceuticals (SYRS) Stock Forecast, Price Target & Predictions
SYRS Stock Forecast
Syros Pharmaceuticals stock forecast is as follows: an average price target of $16.67 (represents a 586.01% upside from SYRS’s last price of $2.43) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
SYRS Price Target
The average price target for Syros Pharmaceuticals (SYRS) is $16.67 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $5.00. This represents a potential 586.01% upside from SYRS's last price of $2.43.
SYRS Analyst Ratings
According to 7 Wall Street analysts, Syros Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for SYRS stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Syros Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 23, 2024 | Edward Tenthoff | Piper Sandler | $5.00 | $2.47 | 102.43% | 105.76% |
| Jun 26, 2024 | Edward Tenthoff | Piper Sandler | $13.00 | $5.70 | 128.07% | 434.98% |
| Jun 26, 2024 | Andrew Fein | H.C. Wainwright | $15.00 | $5.70 | 163.16% | 517.28% |
| Aug 09, 2022 | Mark Breidenbach | Oppenheimer | $30.00 | $9.27 | 223.52% | 1134.57% |
The latest Syros Pharmaceuticals stock forecast, released on Oct 23, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $5.00, which represents a 102.43% increase from the stock price at the time of the forecast ($2.47), and a 105.76% increase from SYRS last price ($2.43).
Syros Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $5.00 | $5.00 | $11.00 |
| Last Closing Price | $2.43 | $2.43 | $2.43 |
| Upside/Downside | 105.76% | 105.76% | 352.67% |
In the current month, the average price target of Syros Pharmaceuticals stock is $5.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 105.76% increase as opposed to Syros Pharmaceuticals's last price of $2.43. This month's average price target is down 0.00% compared to last quarter, and down -54.55% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 26, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 26, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 26, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 25, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Jan 05, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 19, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 09, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| May 17, 2022 | Alliance Global Partners | Buy | Buy | Hold |
| May 03, 2022 | Raymond James | Outperform | Outperform | Hold |
Syros Pharmaceuticals's last stock rating was published by Piper Sandler on Oct 23, 2024. The company gave SYRS a "Overweight" rating, the same as its previous rate.
Syros Pharmaceuticals Financial Forecast
Syros Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $3.76M | $2.83M | $2.95M | $-5.47M | $3.89M | $6.28M | $5.47M | $7.80M | $5.70M | $5.16M | $4.83M | $5.70M | $3.83M | $3.19M | $2.38M | $508.00K | $558.00K | $462.00K | $454.00K | $370.00K | $1.10M |
| Avg Forecast | - | - | - | - | $360.00K | $360.00K | $460.00K | $720.00K | $2.00M | $3.94M | $3.50M | $3.30M | $3.85M | $5.18M | $4.74M | $4.92M | $4.81M | $4.49M | $4.13M | $2.67M | $2.64M | $2.54M | $1.90M | $1.87M | $691.29K | $441.17K | $430.29K | $430.29K | $300.63K | $1.33M |
| High Forecast | - | - | - | - | $360.00K | $360.00K | $460.00K | $720.00K | $2.92M | $3.94M | $3.50M | $3.30M | $3.85M | $5.18M | $4.74M | $4.92M | $4.81M | $4.49M | $4.13M | $2.67M | $2.64M | $2.54M | $1.90M | $1.87M | $691.29K | $441.17K | $430.29K | $430.29K | $360.75K | $1.59M |
| Low Forecast | - | - | - | - | $360.00K | $360.00K | $460.00K | $720.00K | $1.08M | $3.94M | $3.50M | $3.30M | $3.85M | $5.18M | $4.74M | $4.92M | $4.81M | $4.49M | $4.13M | $2.67M | $2.64M | $2.54M | $1.90M | $1.87M | $691.29K | $441.17K | $430.29K | $430.29K | $240.50K | $1.06M |
| # Analysts | - | - | - | - | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.95% | 0.81% | 0.89% | -1.42% | 0.75% | 1.32% | 1.11% | 1.62% | 1.27% | 1.25% | 1.81% | 2.16% | 1.50% | 1.68% | 1.27% | 0.73% | 1.26% | 1.07% | 1.06% | 1.23% | 0.83% |
Syros Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $2.00M, with a low forecast of $1.08M, and a high forecast of $2.92M. SYRS's average Quarter revenue forecast represents a -46.84% decrease compared to the company's last Quarter revenue of $3.76M (Sep 23).
Syros Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-34.64M | $-34.00M | $-30.80M | $-33.63M | $-38.34M | $-32.93M | $-25.87M | $-22.05M | $-24.28M | $-20.77M | $-12.53M | $-29.36M | $-18.72M | $-16.44M | $-16.48M | $-18.83M | $-19.15M | $-18.81M | $-15.93M | $-14.07M | $-11.15M |
| Avg Forecast | - | - | - | - | $-360.00K | $-360.00K | $-460.00K | $-720.00K | $-2.00M | $-3.94M | $-3.50M | $-3.30M | $-3.85M | $-5.18M | $-4.74M | $-4.92M | $-4.81M | $-4.49M | $-4.13M | $-16.92M | $-2.64M | $-2.54M | $-1.90M | $-18.02M | $-691.29K | $-441.17K | $-430.29K | $-18.16M | $-10.83M | $-13.04M |
| High Forecast | - | - | - | - | $-360.00K | $-360.00K | $-460.00K | $-720.00K | $-1.08M | $-3.94M | $-3.50M | $-3.30M | $-3.85M | $-5.18M | $-4.74M | $-4.92M | $-4.81M | $-4.49M | $-4.13M | $-13.53M | $-2.64M | $-2.54M | $-1.90M | $-14.41M | $-691.29K | $-441.17K | $-430.29K | $-14.53M | $-8.66M | $-10.43M |
| Low Forecast | - | - | - | - | $-360.00K | $-360.00K | $-460.00K | $-720.00K | $-2.92M | $-3.94M | $-3.50M | $-3.30M | $-3.85M | $-5.18M | $-4.74M | $-4.92M | $-4.81M | $-4.49M | $-4.13M | $-20.30M | $-2.64M | $-2.54M | $-1.90M | $-21.62M | $-691.29K | $-441.17K | $-430.29K | $-21.80M | $-12.99M | $-15.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | 8.79% | 9.71% | 9.33% | 8.74% | 7.40% | 6.95% | 5.25% | 4.59% | 5.41% | 5.02% | 0.74% | 11.13% | 7.36% | 8.64% | 0.91% | 27.24% | 43.41% | 43.71% | 0.88% | 1.30% | 0.86% |
undefined analysts predict SYRS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Syros Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Syros Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | $-40.14M | - | $-14.92M | $27.57M | $-21.05M | $-35.19M | $-23.64M | $-24.80M | $-26.03M | $-22.49M | $-14.23M | $-30.13M | $-19.49M | $-17.20M | $-17.23M | $-19.73M | $-19.79M | $-19.45M | $-16.46M | $-14.46M | $-11.52M |
| Avg Forecast | $-29.98M | $-28.80M | $-28.54M | $-27.75M | $-28.12M | $-26.56M | $-30.14M | $-33.27M | $-44.92M | $-44.77M | $-44.30M | $-41.17M | $-48.11M | $-152.52M | $-160.22M | $-184.57M | $-181.76M | $-171.80M | $-145.30M | $-19.21M | $-195.86M | $-151.19M | $-158.55M | $-18.83M | $-180.64M | $-181.29M | $-161.00M | $-18.77M | $-11.13M | $-13.47M |
| High Forecast | $-29.98M | $-28.80M | $-28.54M | $-27.75M | $-26.36M | $-26.56M | $-30.14M | $-33.27M | $-39.08M | $-44.77M | $-44.30M | $-41.17M | $-48.11M | $-152.52M | $-160.22M | $-184.57M | $-181.76M | $-171.80M | $-145.30M | $-15.37M | $-195.86M | $-151.19M | $-158.55M | $-15.06M | $-180.64M | $-181.29M | $-161.00M | $-15.02M | $-8.90M | $-10.77M |
| Low Forecast | $-29.98M | $-28.80M | $-28.54M | $-27.75M | $-29.87M | $-26.56M | $-30.14M | $-33.27M | $-50.40M | $-44.77M | $-44.30M | $-41.17M | $-48.11M | $-152.52M | $-160.22M | $-184.57M | $-181.76M | $-171.80M | $-145.30M | $-23.05M | $-195.86M | $-151.19M | $-158.55M | $-22.59M | $-180.64M | $-181.29M | $-161.00M | $-22.53M | $-13.35M | $-16.16M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.90% | - | 0.36% | -0.57% | 0.14% | 0.22% | 0.13% | 0.14% | 0.15% | 0.15% | 0.74% | 0.15% | 0.13% | 0.11% | 0.91% | 0.11% | 0.11% | 0.12% | 0.88% | 1.30% | 0.86% |
Syros Pharmaceuticals's average Quarter net income forecast for Mar 23 is $-41.17M, with a range of $-41.17M to $-41.17M. SYRS's average Quarter net income forecast represents a -249.29% decrease compared to the company's last Quarter net income of $27.57M (Dec 22).
Syros Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | $7.76M | $7.22M | $7.41M | $7.33M | $8.08M | $6.95M | $6.95M | $6.43M | $5.35M | $5.52M | $5.74M | $5.89M | $5.15M | $5.13M | $5.15M | $6.40M | $5.02M | $5.20M | $4.87M | $4.08M | $3.09M |
| Avg Forecast | - | - | - | - | $1.30M | $1.30M | $1.66M | $2.60M | $7.22M | $14.22M | $12.63M | $11.92M | $13.90M | $18.70M | $17.11M | $17.77M | $17.35M | $16.20M | $14.92M | $9.64M | $9.52M | $9.18M | $6.87M | $6.76M | $2.49M | $1.59M | $1.55M | $1.55M | $1.08M | $4.78M |
| High Forecast | - | - | - | - | $1.30M | $1.30M | $1.66M | $2.60M | $10.53M | $14.22M | $12.63M | $11.92M | $13.90M | $18.70M | $17.11M | $17.77M | $17.35M | $16.20M | $14.92M | $9.64M | $9.52M | $9.18M | $6.87M | $6.76M | $2.49M | $1.59M | $1.55M | $1.55M | $1.30M | $5.74M |
| Low Forecast | - | - | - | - | $1.30M | $1.30M | $1.66M | $2.60M | $3.91M | $14.22M | $12.63M | $11.92M | $13.90M | $18.70M | $17.11M | $17.77M | $17.35M | $16.20M | $14.92M | $9.64M | $9.52M | $9.18M | $6.87M | $6.76M | $2.49M | $1.59M | $1.55M | $1.55M | $867.99K | $3.83M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.55% | 0.57% | 0.62% | 0.53% | 0.43% | 0.41% | 0.39% | 0.37% | 0.33% | 0.37% | 0.60% | 0.62% | 0.56% | 0.75% | 0.76% | 2.57% | 3.15% | 3.35% | 3.13% | 3.76% | 0.64% |
Syros Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $7.22M, based on 3 Wall Street analysts, with a range of $3.91M to $10.53M. The forecast indicates a -7.03% fall compared to SYRS last annual SG&A of $7.76M (Sep 23).
Syros Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 15 | 9 | 9 | 8 | 8 | 12 | 16 | 19 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.43 | $-1.30 | $-0.54 | $5.99 | $-2.24 | $-5.51 | $-3.75 | $-3.94 | $-4.14 | $-3.58 | $-2.32 | $-4.91 | $-4.26 | $-3.76 | $-3.92 | $-4.49 | $-4.66 | $-4.67 | $-4.87 | $-4.77 | $-4.92 |
| Avg Forecast | $-0.76 | $-0.73 | $-0.73 | $-0.71 | $-0.72 | $-0.68 | $-0.77 | $-0.85 | $-1.14 | $-1.14 | $-1.13 | $-1.05 | $-1.23 | $-3.88 | $-4.08 | $-4.70 | $-4.63 | $-4.38 | $-3.70 | $-4.64 | $-4.99 | $-3.85 | $-4.04 | $-4.21 | $-4.60 | $-4.62 | $-4.10 | $-5.60 | $-0.30 | $-0.69 |
| High Forecast | $-0.76 | $-0.73 | $-0.73 | $-0.71 | $-0.67 | $-0.68 | $-0.77 | $-0.85 | $-1.00 | $-1.14 | $-1.13 | $-1.05 | $-1.23 | $-3.88 | $-4.08 | $-4.70 | $-4.63 | $-4.38 | $-3.70 | $-4.64 | $-4.99 | $-3.85 | $-4.04 | $-4.21 | $-4.60 | $-4.62 | $-4.10 | $-5.60 | $-0.24 | $-0.55 |
| Low Forecast | $-0.76 | $-0.73 | $-0.73 | $-0.71 | $-0.76 | $-0.68 | $-0.77 | $-0.85 | $-1.28 | $-1.14 | $-1.13 | $-1.05 | $-1.23 | $-3.88 | $-4.08 | $-4.70 | $-4.63 | $-4.38 | $-3.70 | $-4.64 | $-4.99 | $-3.85 | $-4.04 | $-4.21 | $-4.60 | $-4.62 | $-4.10 | $-5.60 | $-0.36 | $-0.83 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.25% | 1.15% | 0.52% | -4.89% | 0.58% | 1.35% | 0.80% | 0.85% | 0.95% | 0.97% | 0.50% | 0.98% | 1.11% | 0.93% | 0.93% | 0.98% | 1.01% | 1.14% | 0.87% | 15.89% | 7.13% |
According to 1 Wall Street analysts, Syros Pharmaceuticals's projected average Quarter EPS for Mar 23 is $-1.05, with a low estimate of $-1.05 and a high estimate of $-1.05. This represents a -117.50% decrease compared to SYRS previous annual EPS of $5.99 (Dec 22).
Syros Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CHRS | Coherus BioSciences | $0.67 | $9.00 | 1243.28% | Hold |
| PASG | Passage Bio | $0.60 | $6.00 | 900.00% | Buy |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| SPRO | Spero Therapeutics | $1.29 | $10.00 | 675.19% | Buy |
| SYRS | Syros Pharmaceuticals | $2.43 | $16.67 | 586.01% | Buy |
| BDTX | Black Diamond Therapeutics | $2.99 | $14.75 | 393.31% | Buy |
| RGNX | REGENXBIO | $8.76 | $34.00 | 288.13% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
| KZR | Kezar Life Sciences | $7.09 | $17.50 | 146.83% | Buy |
| STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
| XNCR | Xencor | $21.52 | $42.60 | 97.96% | Buy |
| SNDX | Syndax Pharmaceuticals | $18.94 | $36.11 | 90.65% | Buy |
| KROS | Keros Therapeutics | $59.95 | $102.00 | 70.14% | Buy |
| IDYA | IDEAYA Biosciences | $30.00 | $48.36 | 61.20% | Buy |
| BOLT | Bolt Biotherapeutics | $0.67 | $1.00 | 49.25% | Hold |
| CRNX | Crinetics Pharmaceuticals | $56.82 | $70.14 | 23.44% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
SYRS Forecast FAQ
Is Syros Pharmaceuticals a good buy?
Yes, according to 7 Wall Street analysts, Syros Pharmaceuticals (SYRS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of SYRS's total ratings.
What is SYRS's price target?
Syros Pharmaceuticals (SYRS) average price target is $16.67 with a range of $5 to $30, implying a 586.01% from its last price of $2.43. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Syros Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for SYRS stock, the company can go up by 586.01% (from the last price of $2.43 to the average price target of $16.67), up by 1134.57% based on the highest stock price target, and up by 105.76% based on the lowest stock price target.
Can Syros Pharmaceuticals stock reach $4?
SYRS's average twelve months analyst stock price target of $16.67 supports the claim that Syros Pharmaceuticals can reach $4 in the near future.
What is Syros Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $5 price target for Syros Pharmaceuticals (SYRS) this month, up 105.76% from its last price of $2.43. Compared to the last 3 and 12 months, the average price target increased by 105.76% and increased by 352.67%, respectively.
What are Syros Pharmaceuticals's analysts' financial forecasts?
Syros Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.9M (high $1.9M, low $1.9M), average EBITDA is $-1.9M (high $-1.9M, low $-1.9M), average net income is $-118M (high $-116M, low $-120M), average SG&A $6.86M (high $6.86M, low $6.86M), and average EPS is $-3.007 (high $-2.962, low $-3.052). SYRS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-115M (high $-115M, low $-115M), average SG&A $0 (high $0, low $0), and average EPS is $-2.93 (high $-2.93, low $-2.93).
Did the SYRS's actual financial results beat the analysts' financial forecasts?
Based on Syros Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $9.94M, which missed the average analysts forecast of $12.74M by -22.02%. Apple's EBITDA was $-129M, beating the average prediction of $-12.742M by 912.33%. The company's net income was $0, missing the average estimation of $-175M by -100.00%. Apple's SG&A was $28.28M, missing the average forecast of $45.99M by -38.50%. Lastly, the company's EPS was $-5.81, beating the average prediction of $-4.46 by 30.26%. In terms of the last quarterly report (Sep 2023), Syros Pharmaceuticals's revenue was $3.76M, missing the average analysts' forecast of $3.94M by -4.52%. The company's EBITDA was $-34.636M, beating the average prediction of $-3.94M by 779.09%. Syros Pharmaceuticals's net income was $-40.143M, missing the average estimation of $-44.767M by -10.33%. The company's SG&A was $7.76M, missing the average forecast of $14.22M by -45.40%. Lastly, the company's EPS was $-1.43, beating the average prediction of $-1.14 by 25.44%